/Press Releases

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference

-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]

2017-10-31T01:12:48+00:00 October 31st, 2017|

Forge therapeutics announces participation in upcoming scientific and industry events

San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and [...]

2017-10-24T00:35:50+00:00 October 23rd, 2017|

Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas

- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships –  [...]

2017-10-12T15:06:06+00:00 October 17th, 2017|

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., [...]

2017-10-09T16:55:18+00:00 October 11th, 2017|

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017

San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data [...]

2017-10-06T18:31:58+00:00 September 7th, 2017|

Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference

San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced today that the [...]

2017-10-04T14:17:29+00:00 August 29th, 2017|

Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts

San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-09T22:00:57+00:00 July 25th, 2017|

Forge and Evotec Present First Efficacy Data for LpxC Inhibitor in UTI Model at ASM Microbe 2017

San Diego, California, June 3, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-11T16:19:13+00:00 June 3rd, 2017|
Load More Posts